Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients

Transplantation

Volumn 97, Issue 6, 2014, Pages 636-641

  Silva, Hélio Tedesco ^a   Yang, Harold C ^b   Meier Kriesche, Herwig Ulf ^c   Croy, Richard ^c   Holman, John ^c   Fitzsimmons, William E ^c   First, M Roy ^c  

^a HOSPITAL DO RIM E HIPERTENSÃO   (Brazil)

^b Pinnacle Health System   (United States)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

De novo kidney transplantation; Long term follow up; Tacrolimus

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; GRACEPTOR; HEMOGLOBIN A1C; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACTERIAL INFECTION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS COLITIS; CYTOMEGALOVIRUS GASTRIRIS; CYTOMEGALOVIRUS GASTRITIS; CYTOMEGALOVIRUS INFECTION; DEATH; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTENDED RELEASE FORMULATION; FEMALE; FOLLOW UP; GINGIVA HYPERPLASIA; GLOMERULUS FILTRATION RATE; GLUCOSE INTOLERANCE; GRAFT FAILURE; GRAFT SURVIVAL; HEPATOBILIARY DISEASE; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LIVER DYSFUNCTION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MYCOSIS; NEOPLASM; NEUROPATHY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN CANCER; SURVIVAL RATE; TREMOR; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE; URINARY TRACT INFECTION; VIREMIA; VIRUS INFECTION;

ADULT; CYCLOSPORINE; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; ILLINOIS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RISK FACTORS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84897023826     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000437669.93963.8E     Document Type: Article

References (18)

1. Silva HT, Yang HC, Abouljoud M, et al. One-year results with extendedrelease tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007; 7: 595.
2. De Geest S, Borgermans L, Gemoets H, et al. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation 1995; 59: 340.
3. Weng FL, Israni AK, Joffe MM, et al. Race and electronically measured adherence to immunosuppressive medication after deceased donor renal transplantation. J Am Soc Nephrol 2005; 16: 1839.
4. Krämer BK, Charpentier B, Bäckman L, et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: A randomized phase III study. Am J Transplant 2010; 10: 2632.
5. Trunecka P, Boillot O, Seehofer D, et al. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tracrolimus (PROGRAF) in liver transplantation. Am J Transplant 2010; 10: 2313.
6. Yang H. A phase III, randomized, open-label, comparative, multicenter study to assess the safety and efficacy of Prograf\ (tacrolimus)/ MMF, extended release (XL) tacrolimus/MMF and Neoral\ (cyclosporine)/ MMF in de novo kidney transplant recipients: 2 year results (Abstr #144). Am J Transplant 2007;7(suppl 2): 183.
7. Nathan DM, Balkau B, Bonora E, et al. Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32: 1327.
8. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2010 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2011.
9. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: Observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876.
10. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12: 210.
11. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
12. Kaplan B, Schold JD, Meier-Kriesche HU. Long-Term graft survival with neoral and tacrolimus: A paired kidney analysis. J Am Soc Nephrol 2003; 14: 2980.
13. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178.
14. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506.
15. First MR, Dhadda S, Croy R, et al. New onset diabetes after transplantation (NODAT): An evaluation of definitions in clinical trials. Transplantation 2013; 96: 58.
16. Albano L, Banas B, Klempnauer JL, et al. OSAKA trial: A randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. Transplantation 2013; doi: 10.1097/TP.0b013e3182a203bd).
17. Ho ETL, Wong G, Craig JC, et al. Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients. Transplantation 2013; 95: 1120.
18. van Gelder T, Klupp J, Barten MT, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23: 119.